Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset
Response Rate:
Petosemtamab achieved a 40.4% overall response rate in evaluable patients with recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) at the 1500mg dose12.
Survival Metrics:
The treatment showed a median overall survival of 12.5 months and a median duration of response of 7.2 months12.
Dose Comparison:
The 1500mg dose demonstrated superior efficacy compared to the 1100mg dose, with 5 responses (including 1 complete response) in 12 evaluable patients at 1500mg versus 1 confirmed response in 10 patients at 1100mg12.
Safety Profile:
Petosemtamab was well-tolerated at both doses, with no grade 5 adverse events reported12.
Clinical Significance:
The interim Phase 2 data supports petosemtamab's potential as a new standard of care for 2L+ r/m HNSCC patients12.
Sources:
1. https://www.stocktitan.net/news/MRUS/merus-announces-publication-of-an-abstract-on-petosemtamab-as-2l-o1bh91qlurim.html
2. https://ir.merus.nl/news-releases/news-release-details/merus-announces-publication-abstract-petosemtamab-2l-treatment